Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy
FUTURE ONCOLOGY, cilt.17, sa.33, ss.4447-4456, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 17 Sayı: 33
- Basım Tarihi: 2021
- Doi Numarası: 10.2217/fon-2021-0597
- Dergi Adı: FUTURE ONCOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
- Sayfa Sayıları: ss.4447-4456
- Anahtar Kelimeler: cancer, chemotherapy, COVID-19, immunogenicity, immunotherapy, monoclonal antibody, safety, tumors, vaccine
- Gazi Üniversitesi Adresli: Evet
Özet
Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 mu g/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as 'immunogenicity.' Results: The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio: 0.830; p = 0.043). Conclusion: More than half of cancer patients receiving active systemic therapy developed immunogenicity.